Investors with the goal of beating the broader market often turn to stock selection. Strategic choices in individual stocks can have a profound impact on your wealth.
As of close of business last night, BioXcel Therapeutics Inc’s stock clocked out at $2.05, up 1.49% from its previous closing price of $2.02. In other words, the price has increased by $1.49 from its previous closing price. On the day, 0.55 million shares were traded. BTAI stock price reached its highest trading level at $2.07 during the session, while it also had its lowest trading level at $1.98.
Ratios:
To gain a deeper understanding of BTAI’s stock, we examine its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 0.74 and its Current Ratio is at 0.76.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of . The stock’s future direction. In the most recent recommendation for the company, UBS on February 21, 2024, Downgraded its rating to Neutral and sets its target price to $4 from $9 previously.
On August 15, 2023, Mizuho Downgraded its rating to Neutral which previously was Buy and also lowered its target price recommendation from $40 to $4.
Insider Transactions:
Investing in insider trades can also provide an investor with insight into how management views future stock prices. A recent insider transaction in this stock occurred on Dec 16 ’24 when O’Neill Vincent sold 165 shares for $0.35 per share. The transaction valued at 58 led to the insider holds 19,957 shares of the business.
Mehta Vimal sold 3,117 shares of BTAI for $1,131 on Dec 16 ’24. The CEO and President now owns 59,605 shares after completing the transaction at $0.36 per share. On Dec 16 ’24, another insider, Steinhart Richard I, who serves as the Chief Financial Officer of the company, sold 577 shares for $0.36 each. As a result, the insider received 207 and left with 20,932 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, BTAI now has a Market Capitalization of 40275940 and an Enterprise Value of 121347320. For the stock, the TTM Price-to-Sale (P/S) ratio is 46.30. Its current Enterprise Value per Revenue stands at 139.801 whereas that against EBITDA is -2.434.
Stock Price History:
The Beta on a monthly basis for BTAI is 0.21, which has changed by -0.80135655 over the last 52 weeks, in comparison to a change of 0.19736934 over the same period for the S&P500. Over the past 52 weeks, BTAI has reached a high of $12.16, while it has fallen to a 52-week low of $1.17. The 50-Day Moving Average of the stock is -31.23%, while the 200-Day Moving Average is calculated to be -21.84%.
Shares Statistics:
It appears that BTAI traded 9.73M shares on average per day over the past three months and 743400 shares per day over the past ten days. A total of 19.65M shares are outstanding, with a floating share count of 18.89M. Insiders hold about 3.84% of the company’s shares, while institutions hold 8.53% stake in the company. Shares short for BTAI as of 1760486400 were 1141061 with a Short Ratio of 0.12, compared to 1757894400 on 1443374. Therefore, it implies a Short% of Shares Outstanding of 1141061 and a Short% of Float of 5.96.
Earnings Estimates
Current recommendations for the stock of the company come from 3.0 analysts. The consensus estimate for the next quarter is -$0.69, with high estimates of -$0.61 and low estimates of -$0.82.
Analysts are recommending an EPS of between -$3.67 and -$8.17 for the fiscal current year, implying an average EPS of -$5.43. EPS for the following year is -$3.55, with 4.0 analysts recommending between -$2.07 and -$7.52.
Revenue Estimates
In . The current quarter, 4 analysts expect revenue to total $197.5k. It ranges from a high estimate of $300k to a low estimate of $140k. As of . The current estimate, BioXcel Therapeutics Inc’s year-ago sales were $214kFor the next quarter, 4 analysts are estimating revenue of $270k. There is a high estimate of $400k for the next quarter, whereas the lowest estimate is $200k.
A total of 5 analysts have provided revenue estimates for BTAI’s current fiscal year. The highest revenue estimate was $900k, while the lowest revenue estimate was $638k, resulting in an average revenue estimate of $722.79k. In the same quarter a year ago, actual revenue was $2.27MBased on 5 analysts’ estimates, the company’s revenue will be $2.69M in the next fiscal year. The high estimate is $6.08M and the low estimate is $700k.
